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value of LE during lead optimization should be maintained above 0.3. It is recommended to start with a fragment or hit which has a higher value of LE because LE normally decreases as long as optimization continues. Undoubtedly, lipophilic ligand efficiency (LLE) is the most important metric in hit optimization and is calculated by subtracting logD value of a compound from the negative logarithm of its potency (usually in IC 50 or K i form in molar concentration) against a specific target. This concept was first proposed by Leeson and Springthorpe [6] . With this metric tool, we can say whether increase in potency is mediated by an increase in lipophilicity or not. Compounds which have an increase in potency during optimization but with constant LLE, shows that possibly this increase in potency is the result of increasing in lipophilicity. Specifically, increasing in LLE indicates that increasing in potency is much more than the increase in lipophilicity (logD). Several studies have reported the correlation of compound high lipophilicity to the likelihood of off-target binding or promiscuous binding to proteins. This phenomenon usually tends to adverse effects, toxicity, reduced selectivity, and poor ADME profile [7, 8] .
Someone may think that increasing polarity of a molecule would be a reasonable way to increase LLE but in fact, decreasing compound lipophilicity often results in potency loss due to desolvation penalty or loss of hydrophobic binding site interactions. Therefore, adding a polar group in order to reduce lipophilicity (logD) should be done with care and is recommended to occur at a point where locates in solvent-accessible region of a molecule. Polar groups at solventexposed region of a molecule do not need to be desolvated when bound to the target because it is outside of binding site space. Therefore, a common strategy to increase LLE without changing potency or affinity is modification of solvent accessible part of a molecule by reducing logD [9] . The suggested range of LLE is 5-7
Fragment based drug discovery (FBDD) has overcome major problems of lead discovery in high throughput screening (HTS) due to its higher chance of hit finding. The higher hit rate of FBDD is attributed to its smaller chemical space and higher chance of complementarity of fragments to the shape of binding site [1] .
In a FBDD project, as hits are grown and linked together to become leads and drug candidates, their lipophilicity and molecular size increases inevitably to increase affinity and potency. In this sense, increase in lipophilicity has many drawbacks such as off-target and non-selective binding, side effects and violations of Lipinski's rule of 5 or drug likeness properties. Similarly, increasing in molecular weight lowers solubility and permeability of oral drugs and reduces druglikeness properties [2] .
Normally, most medicinal chemists only consider potency and try to increase it during hit and lead optimization or when studying structure-activity relationship. Notably, lipophilicity should be considered along with potency variations to avoid lipophilicity violations. Accordingly, scientists have developed ligand efficiency (LE) and lipophilic ligand efficiency (LLE) concepts as a useful metric in lead discovery and optimization and these parameters can be calculated by the following equations. LE = -ΔG b /HA LLE = -log(potency)-logD In order to prevent hit compounds to become larger during optimization, ligand efficiency (LE) can be used to assess binding affinity contribution of each non-hydrogen atom (heavy atom). This parameter was first proposed by Kuntz and coworkers [3] and was further developed by Hann and Keseru [4] and then Hopkins et al. [5] . This metric parameter is calculated by negative of the free energy of binding (-ΔG b ) divided by the number of heavy atoms. The accepted
